A study to develop a prospective multi-site registry to evaluate clinical features, types of treatment, outcomes and survival in participants with HER2 positive metastatic breast cancer managed in routine practice in Australia

BioGrid Australia Ltd0 个研究点目标入组 300 人开始时间: 2015年3月13日最近更新: 2020年1月13日

试验速览

暂无简介。

•Patients of any age and any level of fitness with HER2+ metastatic breast cancer, of any hormone receptor status, either recurrent or de novo metastatic disease, who have either been diagnosed with metastatic disease within the last 3-6 months or who have progressed on 1st line therapy in the last 3-6 months

•- Patients with HER2+ metastatic breast cancer who have received more than two lines of therapy already
•- Patients who are not Australian citizens or are otherwise ineligible for systemic treatment subsidised by the Pharmaceutical Benefit Scheme

发起方

BioGrid Australia Ltd